“Preventive genomics is not yet recommended as standard of care,” Robert Green, director of the Preventive Genomics Clinic, said in a statement. “But for over two decades, our NIH-funded, randomized trials in translational genomics have generated consistent evidence that there are more potential medical benefits and fewer risks than previously considered. It is time for this technology to be offered in a clinical context, under the care of genetics experts, to individuals who wish to be proactive about their health.”
